Suresh Pola MD
Inflammatory Bowel Disease
Staff Physician, Gastroenterology, Kaiser Permanente San Diego
Join to View Full Profile
9500 Gilman DrDept 63La Jolla, CA 92093
Phone+1 858-552-8585
Fax+1 858-552-4327
Dr. Pola is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Pola is a partner physician with Southern California Permanente Medical Group and practices at Kaiser Permanente San Diego. He is a board certified gastroenterologist and internist and has undergone advanced training in inflammatory bowel diseases under the direction of William Sandborn at University of California San Diego.
Education & Training
University of California (San Diego) Medical CenterFellowship, Gastroenterology, 2009 - 2012
University of California (San Francisco)Residency, Internal Medicine, 2006 - 2009
Case Western Reserve University School of MedicineClass of 2006
Certifications & Licensure
CA State Medical License 2008 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Physician of the Year Crohns and Colitis Foundation San Diego, 2019
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Publications & Presentations
PubMed
- 15 citationsImmunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.Robert Battat, Dana J. Lukin, Ellen Scherl, Suresh Pola, Anand Kumar
Inflammatory Bowel Diseases. 2021-08-19 - 2 citationsRetrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States.Joshua T Smith, Fernando S Velayos, Fang Niu, Vincent Liu, Thomas Delate
Crohn's & Colitis 360. 2021-07-01 - 1 citationsCorrection to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare ...Stephanie L Ho, Fang Niu, Suresh Pola, Fernando S Velayos, Xian Ning
Biodrugs. 2020-06-01
Press Mentions
The AMA Does Not Speak for UsDecember 9th, 2016
Other Languages
- French, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
